原癌基因bcl-6在淋巴组织增生性疾病中表达及意义  

Expression and signification of bcl-6 oncogene in lymphoproliferative disorders

作　　者：陶琨[1] 朱雄增[1] 徐薇苓[1] 陈忠伟[1] 陆洪芬[1] 

机构地区：[1]上海医科大学肿瘤医院病理科,现在上海纺一医院病理科200032

出　　处：《临床与实验病理学杂志》2000年第2期93-95,共3页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的 :了解原癌基因bcl 6在一组淋巴组织增生性疾病中表达情况 ,探讨弥漫性大B细胞淋巴瘤的发病机制和bcl 6表达在鉴别诊断中的意义。方法 :观察 112例淋巴组织增生性疾病的组织病理学形态及分型和检测bcl 6表达。结果 :9例淋巴结反应性增生的生发中心细胞、12例滤泡性淋巴瘤和 16例中心细胞中心母细胞淋巴瘤的肿瘤细胞均可表达bcl 6 ,表达强度多为弱阳性 ,阳性率和阳性强度差别无统计学意义 (P >0 0 5 ) ;6 0例弥漫性大B细胞淋巴瘤表达阳性率 95 % ,表达强度为中等阳性或强阳性 ,与前一组相比差别有统计学意义 (P <0 0 1) ;5例套细胞淋巴瘤 ,6例典型霍奇金淋巴瘤及 4例外周T细胞淋巴瘤均不表达bcl 6。结论 :弥漫性大B细胞淋巴瘤显著表达bcl 6 ,表达强度高于淋巴结反应性增生、滤泡性淋巴瘤和中心细胞中心母细胞淋巴瘤 ,bcl 6的过度表达可能与其发病有关。bcl 6的表达对反应性增生和滤泡性淋巴瘤的鉴别诊断无意义 ,但对滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤的鉴别有辅助作用。Purpose To study the expression of oncogene bcl 6 in a group of lymphoproliferative disorders, to elucidate the pathogenesis of diffuse large B cell lymphoma (B DLCL) and significance of differential diagnosis of bcl 6. Methods The histomorphology and immunophcnotype of 112 cases of lymphoproliferative disorder were examined and typed. EnVision TM immunohistochemical methods were employed to detect the bcl 6. Results The follicular cells in 9 cases of lymph node reactive hyperplasia and tumor cells in 12 cases of follicular lymphoma (FL) and 16 cases of centroblastic and centrocytic lymphoma(CB CC) expressed bcl 6 weakly and there was no statistical signification (P>0 05). Fifty seven of 60(95%) cases of diffuse large B cell lymphoma (B DLCL) were bcl 6 positive with moderate or intensive expression. The difference between the B DLCL and above mentioned groups was significant(P<0 01). There was no expression of bcl 6 in 5 cases of mantle cell lymphoma (MCL),6 cases of Hodgkins lymphoma(HL) and 4 cases of peripheral T cell lymphoma(PTCL). Conclusion Overexpression of bcl 6 in B DLCL may be related with its pathogenesis and bcl 6 immunohistochemistry may play a ancillary role in differential diagnosis in FL and B DLCL.

关 键 词：淋巴瘤 BCL-6基因 基因表达 淋巴组织增生病 

分 类 号：R733.102[医药卫生—肿瘤]